ID   AKT2_HUMAN              Reviewed;         481 AA.
AC   P31751; B2RBD8; Q05BV0; Q0VAN0; Q0VAN1; Q68GC0;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 2.
DT   12-OCT-2022, entry version 229.
DE   RecName: Full=RAC-beta serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase Akt-2;
DE   AltName: Full=Protein kinase B beta;
DE            Short=PKB beta;
DE   AltName: Full=RAC-PK-beta;
GN   Name=AKT2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Epithelium;
RX   PubMed=1801921; DOI=10.1091/mbc.2.12.1001;
RA   Jones P.F., Jakubowicz T., Hemmings B.A.;
RT   "Molecular cloning of a second form of rac protein kinase.";
RL   Cell Regul. 2:1001-1009(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1409633; DOI=10.1073/pnas.89.19.9267;
RA   Cheng J.Q., Godwin A.K., Bellacosa A., Taguchi T., Franke T.F.,
RA   Hamilton T.C., Tsichlis P.N., Testa J.R.;
RT   "AKT2, a putative oncogene encoding a member of a subfamily of protein-
RT   serine/threonine kinases, is amplified in human ovarian carcinomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:9267-9271(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 237-277.
RG   NIEHS SNPs program;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   CHARACTERIZATION, AND PHOSPHORYLATION AT THR-309 BY PDPK1.
RX   PubMed=9512493; DOI=10.1042/bj3310299;
RA   Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.;
RT   "Activation of protein kinase B beta and gamma isoforms by insulin in vivo
RT   and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison
RT   with protein kinase B alpha.";
RL   Biochem. J. 331:299-308(1998).
RN   [8]
RP   INTERACTION WITH MTCP1; TCL1A AND TCL1B.
RX   PubMed=10983986; DOI=10.1016/s1097-2765(00)00039-3;
RA   Laine J., Kuenstle G., Obata T., Sha M., Noguchi M.;
RT   "The protooncogene TCL1 is an Akt kinase coactivator.";
RL   Mol. Cell 6:395-407(2000).
RN   [9]
RP   MUTAGENESIS OF THR-309 AND SER-474, AND PHOSPHORYLATION AT THR-309 AND
RP   SER-474.
RX   PubMed=15890450; DOI=10.1016/j.bbagen.2005.04.002;
RA   Baer K., Lisinski I., Gompert M., Stuhlmann D., Schmolz K., Klein H.W.,
RA   Al-Hasani H.;
RT   "Activation of a GST-tagged AKT2/PKBbeta.";
RL   Biochim. Biophys. Acta 1725:340-347(2005).
RN   [10]
RP   INTERACTION WITH WDFY2.
RX   PubMed=16792529; DOI=10.1042/bj20060511;
RA   Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M., Bosse M.,
RA   Zimmermann S., Frey A.D., Caelers A., Bachmann A.S., Moelling K.;
RT   "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda.";
RL   Biochem. J. 399:9-20(2006).
RN   [11]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=16540465; DOI=10.1074/jbc.m601384200;
RA   Zhang X., Zhang S., Yamane H., Wahl R., Ali A., Lofgren J.A., Kendall R.L.;
RT   "Kinetic mechanism of AKT/PKB enzyme family.";
RL   J. Biol. Chem. 281:13949-13956(2006).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PBH2.
RX   PubMed=17565718; DOI=10.1002/jcp.21177;
RA   Heron-Milhavet L., Mamaeva D., Rochat A., Lamb N.J., Fernandez A.;
RT   "Akt2 is implicated in skeletal muscle differentiation and specifically
RT   binds Prohibitin2/REA.";
RL   J. Cell. Physiol. 214:158-165(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-126, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   UBIQUITINATION BY TTC3, PHOSPHORYLATION AT THR-309 AND SER-474, AND
RP   MUTAGENESIS OF THR-309 AND SER-474.
RX   PubMed=20059950; DOI=10.1016/j.devcel.2009.09.007;
RA   Suizu F., Hiramuki Y., Okumura F., Matsuda M., Okumura A.J., Hirata N.,
RA   Narita M., Kohno T., Yokota J., Bohgaki M., Obuse C., Hatakeyama S.,
RA   Obata T., Noguchi M.;
RT   "The E3 ligase TTC3 facilitates ubiquitination and degradation of
RT   phosphorylated Akt.";
RL   Dev. Cell 17:800-810(2009).
RN   [15]
RP   INTERACTION WITH CLIP3, AND SUBCELLULAR LOCATION.
RX   PubMed=19139280; DOI=10.1128/mcb.00754-08;
RA   Ding J., Du K.;
RT   "ClipR-59 interacts with Akt and regulates Akt cellular
RT   compartmentalization.";
RL   Mol. Cell. Biol. 29:1459-1471(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-447; THR-451; SER-474 AND
RP   SER-478, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   UBIQUITINATION, AND INTERACTION WITH TRAF6.
RX   PubMed=19713527; DOI=10.1126/science.1175065;
RA   Yang W.-L., Wang J., Chan C.-H., Lee S.-W., Campos A.D., Lamothe B.,
RA   Hur L., Grabiner B.C., Lin X., Darnay B.G., Lin H.-K.;
RT   "The E3 ligase TRAF6 regulates Akt ubiquitination and activation.";
RL   Science 325:1134-1138(2009).
RN   [18]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=20167810; DOI=10.1093/neuonc/nop026;
RA   Mure H., Matsuzaki K., Kitazato K.T., Mizobuchi Y., Kuwayama K., Kageji T.,
RA   Nagahiro S.;
RT   "Akt2 and Akt3 play a pivotal role in malignant gliomas.";
RL   Neuro-oncol. 12:221-232(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004;
RA   Hers I., Vincent E.E., Tavare J.M.;
RT   "Akt signalling in health and disease.";
RL   Cell. Signal. 23:1515-1527(2011).
RN   [21]
RP   REVIEW ON FUNCTION.
RX   PubMed=21432781; DOI=10.14670/hh-26.651;
RA   Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.;
RT   "Akt1 and Akt2: differentiating the aktion.";
RL   Histol. Histopathol. 26:651-662(2011).
RN   [22]
RP   FUNCTION IN MUSCLE DIFFERENTIATION, AND INTERACTION WITH ANKRD2.
RX   PubMed=21737686; DOI=10.1091/mbc.e10-11-0928;
RA   Cenni V., Bavelloni A., Beretti F., Tagliavini F., Manzoli L., Lattanzi G.,
RA   Maraldi N.M., Cocco L., Marmiroli S.;
RT   "Ankrd2/ARPP is a novel Akt2 specific substrate and regulates myogenic
RT   differentiation upon cellular exposure to H(2)O(2).";
RL   Mol. Biol. Cell 22:2946-2956(2011).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-34 AND SER-126, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-34 AND THR-451, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 146-480.
RX   PubMed=12086620; DOI=10.1016/s1097-2765(02)00550-6;
RA   Yang J., Cron P., Thompson V., Good V.M., Hess D., Hemmings B.A.,
RA   Barford D.;
RT   "Molecular mechanism for the regulation of protein kinase B/Akt by
RT   hydrophobic motif phosphorylation.";
RL   Mol. Cell 9:1227-1240(2002).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 146-467 IN COMPLEX WITH
RP   PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER AND MANGANESE, AND
RP   PHOSPHORYLATION AT THR-309.
RX   PubMed=12434148; DOI=10.1038/nsb870;
RA   Yang J., Cron P., Good V.M., Thompson V., Hemmings B.A., Barford D.;
RT   "Crystal structure of an activated Akt/protein kinase B ternary complex
RT   with GSK3-peptide and AMP-PNP.";
RL   Nat. Struct. Biol. 9:940-944(2002).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 143-481, ATP-BINDING,
RP   SUBSTRATE-BINDING, AND DISULFIDE BOND.
RX   PubMed=12517337; DOI=10.1016/s0969-2126(02)00937-1;
RA   Huang X., Begley M., Morgenstern K.A., Gu Y., Rose P., Zhao H., Zhu X.;
RT   "Crystal structure of an inactive Akt2 kinase domain.";
RL   Structure 11:21-30(2003).
RN   [29]
RP   STRUCTURE BY NMR OF 1-111.
RX   PubMed=14755158; DOI=10.1023/b:jnmr.0000013836.62154.c2;
RA   Auguin D., Barthe P., Auge-Senegas M.T., Stern M.H., Noguchi M.,
RA   Roumestand C.;
RT   "Solution structure and backbone dynamics of the pleckstrin homology domain
RT   of the human protein kinase B (PKB/Akt). Interaction with inositol
RT   phosphates.";
RL   J. Biomol. NMR 28:137-155(2004).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 146-467, AND INHIBITOR-BINDING.
RX   PubMed=17275837; DOI=10.1016/j.jmb.2007.01.004;
RA   Davies T.G., Verdonk M.L., Graham B., Saalau-Bethell S., Hamlett C.C.,
RA   McHardy T., Collins I., Garrett M.D., Workman P., Woodhead S.J., Jhoti H.,
RA   Barford D.;
RT   "A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB
RT   chimera.";
RL   J. Mol. Biol. 367:882-894(2007).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 146-480, AND ACTIVITY REGULATION.
RX   PubMed=18800763; DOI=10.1021/jm8004527;
RA   Heerding D.A., Rhodes N., Leber J.D., Clark T.J., Keenan R.M.,
RA   Lafrance L.V., Li M., Safonov I.G., Takata D.T., Venslavsky J.W.,
RA   Yamashita D.S., Choudhry A.E., Copeland R.A., Lai Z., Schaber M.D.,
RA   Tummino P.J., Strum S.L., Wood E.R., Duckett D.R., Eberwein D., Knick V.B.,
RA   Lansing T.J., McConnell R.T., Zhang S., Minthorn E.A., Concha N.O.,
RA   Warren G.L., Kumar R.;
RT   "Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-
RT   piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol
RT   (GSK690693), a novel inhibitor of AKT kinase.";
RL   J. Med. Chem. 51:5663-5679(2008).
RN   [32] {ECO:0007744|PDB:3E87, ECO:0007744|PDB:3E88, ECO:0007744|PDB:3E8D}
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 146-480, AND ACTIVITY REGULATION.
RX   PubMed=19179070; DOI=10.1016/j.bmcl.2009.01.002;
RA   Rouse M.B., Seefeld M.A., Leber J.D., McNulty K.C., Sun L., Miller W.H.,
RA   Zhang S., Minthorn E.A., Concha N.O., Choudhry A.E., Schaber M.D.,
RA   Heerding D.A.;
RT   "Aminofurazans as potent inhibitors of AKT kinase.";
RL   Bioorg. Med. Chem. Lett. 19:1508-1511(2009).
RN   [33]
RP   VARIANT NIDDM HIS-274.
RX   PubMed=15166380; DOI=10.1126/science.1096706;
RA   George S., Rochford J.J., Wolfrum C., Gray S.L., Schinner S., Wilson J.C.,
RA   Soos M.A., Murgatroyd P.R., Williams R.M., Acerini C.L., Dunger D.B.,
RA   Barford D., Umpleby A.M., Wareham N.J., Davies H.A., Schafer A.J.,
RA   Stoffel M., O'Rahilly S., Barroso I.;
RT   "A family with severe insulin resistance and diabetes due to a mutation in
RT   AKT2.";
RL   Science 304:1325-1328(2004).
RN   [34]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-188 AND LYS-208.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [35]
RP   ASSOCIATION OF VARIANT NIDDM HIS-274 WITH TYPICAL METABOLIC DYSLIPIDEMIA.
RX   PubMed=19164855; DOI=10.1172/jci37432;
RA   Semple R.K., Sleigh A., Murgatroyd P.R., Adams C.A., Bluck L., Jackson S.,
RA   Vottero A., Kanabar D., Charlton-Menys V., Durrington P., Soos M.A.,
RA   Carpenter T.A., Lomas D.J., Cochran E.K., Gorden P., O'Rahilly S.,
RA   Savage D.B.;
RT   "Postreceptor insulin resistance contributes to human dyslipidemia and
RT   hepatic steatosis.";
RL   J. Clin. Invest. 119:315-322(2009).
RN   [36]
RP   VARIANT HIHGHH LYS-17.
RX   PubMed=21979934; DOI=10.1126/science.1210878;
RA   Hussain K., Challis B., Rocha N., Payne F., Minic M., Thompson A., Daly A.,
RA   Scott C., Harris J., Smillie B.J., Savage D.B., Ramaswami U., De Lonlay P.,
RA   O'Rahilly S., Barroso I., Semple R.K.;
RT   "An activating mutation of AKT2 and human hypoglycemia.";
RL   Science 334:474-474(2011).
CC   -!- FUNCTION: AKT2 is one of 3 closely related serine/threonine-protein
CC       kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate
CC       many processes including metabolism, proliferation, cell survival,
CC       growth and angiogenesis. This is mediated through serine and/or
CC       threonine phosphorylation of a range of downstream substrates. Over 100
CC       substrate candidates have been reported so far, but for most of them,
CC       no isoform specificity has been reported. AKT is responsible of the
CC       regulation of glucose uptake by mediating insulin-induced translocation
CC       of the SLC2A4/GLUT4 glucose transporter to the cell surface.
CC       Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its
CC       phosphatase activity preventing dephosphorylation of the insulin
CC       receptor and the attenuation of insulin signaling. Phosphorylation of
CC       TBC1D4 triggers the binding of this effector to inhibitory 14-3-3
CC       proteins, which is required for insulin-stimulated glucose transport.
CC       AKT regulates also the storage of glucose in the form of glycogen by
CC       phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in
CC       inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by
CC       AKT is also thought to be one mechanism by which cell proliferation is
CC       driven. AKT regulates also cell survival via the phosphorylation of
CC       MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83'
CC       decreases MAP3K5 kinase activity stimulated by oxidative stress and
CC       thereby prevents apoptosis. AKT mediates insulin-stimulated protein
CC       synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby
CC       activating mTORC1 signaling and leading to both phosphorylation of 4E-
CC       BP1 and in activation of RPS6KB1. AKT is involved in the
CC       phosphorylation of members of the FOXO factors (Forkhead family of
CC       transcription factors), leading to binding of 14-3-3 proteins and
CC       cytoplasmic localization. In particular, FOXO1 is phosphorylated at
CC       'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated
CC       on equivalent sites. AKT has an important role in the regulation of NF-
CC       kappa-B-dependent gene transcription and positively regulates the
CC       activity of CREB1 (cyclic AMP (cAMP)-response element binding protein).
CC       The phosphorylation of CREB1 induces the binding of accessory proteins
CC       that are necessary for the transcription of pro-survival genes such as
CC       BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase
CC       (ACLY), thereby potentially regulating ACLY activity and fatty acid
CC       synthesis. Activates the 3B isoform of cyclic nucleotide
CC       phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting
CC       in reduced cyclic AMP levels and inhibition of lipolysis.
CC       Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-
CC       5 activity. The Rho GTPase-activating protein DLC1 is another substrate
CC       and its phosphorylation is implicated in the regulation cell
CC       proliferation and cell growth. AKT plays a role as key modulator of the
CC       AKT-mTOR signaling pathway controlling the tempo of the process of
CC       newborn neurons integration during adult neurogenesis, including
CC       correct neuron positioning, dendritic development and synapse
CC       formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K)
CC       to mediate the effects of various growth factors such as platelet-
CC       derived growth factor (PDGF), epidermal growth factor (EGF), insulin
CC       and insulin-like growth factor I (IGF-I). AKT mediates the
CC       antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated
CC       regulation of cell migration and adhesion assembly and disassembly. May
CC       be involved in the regulation of the placental development.
CC   -!- FUNCTION: One of the few specific substrates of AKT2 identified
CC       recently is PITX2. Phosphorylation of PITX2 impairs its association
CC       with the CCND1 mRNA-stabilizing complex thus shortening the half-life
CC       of CCND1. AKT2 seems also to be the principal isoform responsible of
CC       the regulation of glucose uptake. Phosphorylates C2CD5 on 'Ser-197'
CC       during insulin-stimulated adipocytes. AKT2 is also specifically
CC       involved in skeletal muscle differentiation, one of its substrates in
CC       this process being ANKRD2. Down-regulation by RNA interference reduces
CC       the expression of the phosphorylated form of BAD, resulting in the
CC       induction of caspase-dependent apoptosis. Phosphorylates CLK2 on 'Thr-
CC       343'.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Two specific sites, one in the kinase domain (Thr-
CC       309) and the other in the C-terminal regulatory region (Ser-474), need
CC       to be phosphorylated for its full activation (PubMed:18800763,
CC       PubMed:19179070). Aminofurazans, such as 4-[2-(4-amino-2,5-
CC       dihydro-1,2,5-oxadiazol-3-yl)-6-{[(1S)-3-amino-1-phenylpropyl]oxy}-1-
CC       ethyl-1H-imidazo[4,5-c]pyridin-4-yl]-2-methylbut-3-yn-2-ol (compound
CC       32), are potent AKT2 inhibitors (PubMed:19179070).
CC       {ECO:0000269|PubMed:18800763, ECO:0000269|PubMed:19179070}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=358.4 uM for ATP (for purified and in vitro activated AKT2)
CC         {ECO:0000269|PubMed:16540465};
CC         KM=3.4 uM for peptide substrate (for purified and in vitro activated
CC         AKT2) {ECO:0000269|PubMed:16540465};
CC         KM=564 uM for ATP (for recombinant myristoylated AKT2 expressed and
CC         immunoprecipitated from Rat-1 cells) {ECO:0000269|PubMed:16540465};
CC         KM=2.3 uM for peptide substrate (for recombinant myristoylated AKT2
CC         expressed and immunoprecipitated from Rat-1 cells)
CC         {ECO:0000269|PubMed:16540465};
CC   -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with KCTD20
CC       (By similarity). Interacts (via PH domain) with MTCP1, TCL1A and TCL1B.
CC       Interacts with CLK2, PBH2 and TRAF6. Interacts (when phosphorylated)
CC       with CLIP3, the interaction promotes cell membrane localization
CC       (PubMed:19139280). Interacts with WDFY2 (via WD repeats 1-3)
CC       (PubMed:16792529). {ECO:0000250|UniProtKB:Q60823,
CC       ECO:0000269|PubMed:10983986, ECO:0000269|PubMed:12434148,
CC       ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17565718,
CC       ECO:0000269|PubMed:19139280, ECO:0000269|PubMed:19713527,
CC       ECO:0000269|PubMed:21737686}.
CC   -!- INTERACTION:
CC       P31751; P49841: GSK3B; NbExp=2; IntAct=EBI-296058, EBI-373586;
CC       P31751; P08238: HSP90AB1; NbExp=2; IntAct=EBI-296058, EBI-352572;
CC       P31751; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-296058, EBI-16439278;
CC       P31751; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-296058, EBI-79165;
CC       P31751; Q04864-2: REL; NbExp=3; IntAct=EBI-296058, EBI-10829018;
CC       P31751; O60504: SORBS3; NbExp=3; IntAct=EBI-296058, EBI-741237;
CC       P31751; P53804: TTC3; NbExp=5; IntAct=EBI-296058, EBI-2681313;
CC       P31751; P08670: VIM; NbExp=6; IntAct=EBI-296058, EBI-353844;
CC       P31751-1; Q15118-1: PDK1; NbExp=2; IntAct=EBI-12562336, EBI-12562315;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane; Peripheral
CC       membrane protein. Early endosome {ECO:0000250|UniProtKB:Q60823}.
CC       Note=Localizes within both nucleus and cytoplasm of proliferative
CC       primary myoblasts and mostly within the nucleus of differentiated
CC       primary myoblasts. By virtue of the N-terminal PH domain, is recruited
CC       to sites of the plasma membrane containing increased PI(3,4,5)P3 or
CC       PI(3,4)P2, cell membrane targeting is also facilitared by interaction
CC       with CLIP3. Colocalizes with WDFY2 in early endosomes (By similarity).
CC       {ECO:0000250|UniProtKB:Q60823}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P31751-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P31751-2; Sequence=VSP_056930;
CC   -!- TISSUE SPECIFICITY: Expressed in all cell types so far analyzed.
CC   -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-
CC       trisphosphate (PI(3,4,5)P3) following phosphatidylinositol 3-kinase
CC       alpha (PIK3CA) activity results in its targeting to the plasma
CC       membrane.
CC   -!- PTM: Phosphorylation on Thr-309 and Ser-474 is required for full
CC       activity. {ECO:0000269|PubMed:12434148, ECO:0000269|PubMed:15890450,
CC       ECO:0000269|PubMed:20059950, ECO:0000269|PubMed:9512493}.
CC   -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked
CC       polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT2 ubiquitination.
CC       When fully phosphorylated and translocated into the nucleus, undergoes
CC       'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its
CC       degradation by the proteasome. {ECO:0000269|PubMed:19713527,
CC       ECO:0000269|PubMed:20059950}.
CC   -!- PTM: O-GlcNAcylation at Thr-306 and Thr-313 inhibits activating
CC       phosphorylation at Thr-309 via disrupting the interaction between AKT
CC       and PDK1. {ECO:0000250}.
CC   -!- DISEASE: Note=Defects in AKT2 are a cause of susceptibility to breast
CC       cancer (BC). AKT2 promotes metastasis of tumor cells without affecting
CC       the latency of tumor development. With AKT3, also plays a pivotal role
CC       in the biology of glioblastoma.
CC   -!- DISEASE: Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]:
CC       A multifactorial disorder of glucose homeostasis caused by a lack of
CC       sensitivity to the body's own insulin. Affected individuals usually
CC       have an obese body habitus and manifestations of a metabolic syndrome
CC       characterized by diabetes, insulin resistance, hypertension and
CC       hypertriglyceridemia. The disease results in long-term complications
CC       that affect the eyes, kidneys, nerves, and blood vessels.
CC       {ECO:0000269|PubMed:15166380, ECO:0000269|PubMed:19164855}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Hypoinsulinemic hypoglycemia with hemihypertrophy (HIHGHH)
CC       [MIM:240900]: A disorder characterized by hypoglycemia, low insulin
CC       levels, low serum levels of ketone bodies and branched-chain amino
CC       acids, left-sided hemihypertrophy, neonatal macrosomia, reduced
CC       consciousness and hypoglycemic seizures. {ECO:0000269|PubMed:21979934}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. RAC subfamily. {ECO:0000305}.
CC   -!- CAUTION: In light of strong homologies in the primary amino acid
CC       sequence, the 3 AKT kinases were long surmised to play redundant and
CC       overlapping roles. More recent studies has brought into question the
CC       redundancy within AKT kinase isoforms and instead pointed to isoform
CC       specific functions in different cellular events and diseases. AKT1 is
CC       more specifically involved in cellular survival pathways, by inhibiting
CC       apoptotic processes; whereas AKT2 is more specific for the insulin
CC       receptor signaling pathway. Moreover, while AKT1 and AKT2 are often
CC       implicated in many aspects of cellular transformation, the 2 isoforms
CC       act in a complementary opposing manner. The role of AKT3 is less clear,
CC       though it appears to be predominantly expressed in brain.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AKT2ID517ch19q13.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/akt2/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M77198; AAA36585.1; -; mRNA.
DR   EMBL; M95936; AAA58364.1; -; mRNA.
DR   EMBL; AK314619; BAG37185.1; -; mRNA.
DR   EMBL; AC118344; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC032709; AAH32709.1; -; mRNA.
DR   EMBL; BC120995; AAI20996.1; -; mRNA.
DR   EMBL; BC120994; AAI20995.1; -; mRNA.
DR   EMBL; AY708392; AAT97984.1; -; Genomic_DNA.
DR   CCDS; CCDS12552.1; -. [P31751-1]
DR   CCDS; CCDS82350.1; -. [P31751-2]
DR   PIR; A46288; A46288.
DR   RefSeq; NP_001317440.1; NM_001330511.1. [P31751-2]
DR   RefSeq; NP_001617.1; NM_001626.5. [P31751-1]
DR   RefSeq; XP_011524916.1; XM_011526614.1. [P31751-1]
DR   RefSeq; XP_011524917.1; XM_011526615.1. [P31751-1]
DR   RefSeq; XP_011524918.1; XM_011526616.1. [P31751-1]
DR   RefSeq; XP_011524920.1; XM_011526618.1. [P31751-1]
DR   RefSeq; XP_011524921.1; XM_011526619.1. [P31751-1]
DR   RefSeq; XP_011524922.1; XM_011526620.1. [P31751-1]
DR   RefSeq; XP_016881959.1; XM_017026470.1. [P31751-1]
DR   PDB; 1GZK; X-ray; 2.30 A; A=146-460.
DR   PDB; 1GZN; X-ray; 2.50 A; A=146-480.
DR   PDB; 1GZO; X-ray; 2.75 A; A=146-460.
DR   PDB; 1MRV; X-ray; 2.80 A; A=143-481.
DR   PDB; 1MRY; X-ray; 2.80 A; A=143-481.
DR   PDB; 1O6K; X-ray; 1.70 A; A=146-481.
DR   PDB; 1O6L; X-ray; 1.60 A; A=146-467.
DR   PDB; 1P6S; NMR; -; A=1-111.
DR   PDB; 2JDO; X-ray; 1.80 A; A=146-467.
DR   PDB; 2JDR; X-ray; 2.30 A; A=146-467.
DR   PDB; 2UW9; X-ray; 2.10 A; A=146-467.
DR   PDB; 2X39; X-ray; 1.93 A; A=146-467.
DR   PDB; 2XH5; X-ray; 2.72 A; A=146-479.
DR   PDB; 3D0E; X-ray; 2.00 A; A/B=146-480.
DR   PDB; 3E87; X-ray; 2.30 A; A/B=146-480.
DR   PDB; 3E88; X-ray; 2.50 A; A/B=146-480.
DR   PDB; 3E8D; X-ray; 2.70 A; A/B=146-480.
DR   PDBsum; 1GZK; -.
DR   PDBsum; 1GZN; -.
DR   PDBsum; 1GZO; -.
DR   PDBsum; 1MRV; -.
DR   PDBsum; 1MRY; -.
DR   PDBsum; 1O6K; -.
DR   PDBsum; 1O6L; -.
DR   PDBsum; 1P6S; -.
DR   PDBsum; 2JDO; -.
DR   PDBsum; 2JDR; -.
DR   PDBsum; 2UW9; -.
DR   PDBsum; 2X39; -.
DR   PDBsum; 2XH5; -.
DR   PDBsum; 3D0E; -.
DR   PDBsum; 3E87; -.
DR   PDBsum; 3E88; -.
DR   PDBsum; 3E8D; -.
DR   AlphaFoldDB; P31751; -.
DR   BMRB; P31751; -.
DR   SMR; P31751; -.
DR   BioGRID; 106711; 100.
DR   CORUM; P31751; -.
DR   DIP; DIP-32583N; -.
DR   ELM; P31751; -.
DR   IntAct; P31751; 50.
DR   MINT; P31751; -.
DR   STRING; 9606.ENSP00000375892; -.
DR   BindingDB; P31751; -.
DR   ChEMBL; CHEMBL2431; -.
DR   DrugBank; DB08073; (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE.
DR   DrugBank; DB07859; 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE.
DR   DrugBank; DB07947; ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE.
DR   DrugBank; DB07812; N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide.
DR   DrugCentral; P31751; -.
DR   GuidetoPHARMACOLOGY; 1480; -.
DR   GlyGen; P31751; 5 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P31751; -.
DR   PhosphoSitePlus; P31751; -.
DR   BioMuta; AKT2; -.
DR   DMDM; 1170703; -.
DR   CPTAC; CPTAC-788; -.
DR   CPTAC; CPTAC-789; -.
DR   EPD; P31751; -.
DR   jPOST; P31751; -.
DR   MassIVE; P31751; -.
DR   MaxQB; P31751; -.
DR   PaxDb; P31751; -.
DR   PeptideAtlas; P31751; -.
DR   PRIDE; P31751; -.
DR   ProteomicsDB; 54801; -. [P31751-1]
DR   ProteomicsDB; 58804; -.
DR   Antibodypedia; 3775; 1684 antibodies from 49 providers.
DR   CPTC; P31751; 6 antibodies.
DR   DNASU; 208; -.
DR   Ensembl; ENST00000311278.10; ENSP00000309428.6; ENSG00000105221.18. [P31751-2]
DR   Ensembl; ENST00000392038.7; ENSP00000375892.2; ENSG00000105221.18. [P31751-1]
DR   Ensembl; ENST00000424901.5; ENSP00000399532.2; ENSG00000105221.18. [P31751-2]
DR   GeneID; 208; -.
DR   KEGG; hsa:208; -.
DR   MANE-Select; ENST00000392038.7; ENSP00000375892.2; NM_001626.6; NP_001617.1.
DR   UCSC; uc002onf.3; human. [P31751-1]
DR   CTD; 208; -.
DR   DisGeNET; 208; -.
DR   GeneCards; AKT2; -.
DR   HGNC; HGNC:392; AKT2.
DR   HPA; ENSG00000105221; Low tissue specificity.
DR   MalaCards; AKT2; -.
DR   MIM; 125853; phenotype.
DR   MIM; 164731; gene.
DR   MIM; 240900; phenotype.
DR   neXtProt; NX_P31751; -.
DR   OpenTargets; ENSG00000105221; -.
DR   Orphanet; 79085; AKT2-related familial partial lipodystrophy.
DR   Orphanet; 293964; Hypoinsulinemic hypoglycemia and body hemihypertrophy.
DR   PharmGKB; PA24685; -.
DR   VEuPathDB; HostDB:ENSG00000105221; -.
DR   eggNOG; KOG0690; Eukaryota.
DR   GeneTree; ENSGT00940000157189; -.
DR   InParanoid; P31751; -.
DR   OrthoDB; 442523at2759; -.
DR   PhylomeDB; P31751; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; P31751; -.
DR   Reactome; R-HSA-111447; Activation of BAD and translocation to mitochondria.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-HSA-1445148; Translocation of SLC2A4 (GLUT4) to the plasma membrane.
DR   Reactome; R-HSA-165158; Activation of AKT2.
DR   Reactome; R-HSA-165160; PDE3B signalling.
DR   Reactome; R-HSA-165181; Inhibition of TSC complex formation by PKB.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-8876198; RAB GEFs exchange GTP for GDP on RABs.
DR   Reactome; R-HSA-8941332; RUNX2 regulates genes involved in cell migration.
DR   Reactome; R-HSA-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-HSA-9607240; FLT3 Signaling.
DR   Reactome; R-HSA-9614399; Regulation of localization of FOXO transcription factors.
DR   Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling.
DR   Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SABIO-RK; P31751; -.
DR   SignaLink; P31751; -.
DR   SIGNOR; P31751; -.
DR   BioGRID-ORCS; 208; 35 hits in 1116 CRISPR screens.
DR   ChiTaRS; AKT2; human.
DR   EvolutionaryTrace; P31751; -.
DR   GeneWiki; AKT2; -.
DR   GenomeRNAi; 208; -.
DR   Pharos; P31751; Tchem.
DR   PRO; PR:P31751; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P31751; protein.
DR   Bgee; ENSG00000105221; Expressed in right uterine tube and 176 other tissues.
DR   ExpressionAtlas; P31751; baseline and differential.
DR   Genevisible; P31751; HS.
DR   GO; GO:0005938; C:cell cortex; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0032587; C:ruffle membrane; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0140677; F:molecular function activator activity; EXP:DisProt.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0090630; P:activation of GTPase activity; IEA:Ensembl.
DR   GO; GO:0008643; P:carbohydrate transport; IEA:UniProtKB-KW.
DR   GO; GO:0071486; P:cellular response to high light intensity; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL.
DR   GO; GO:0045444; P:fat cell differentiation; TAS:UniProtKB.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0065002; P:intracellular protein transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; TAS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; IMP:BHF-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0032287; P:peripheral nervous system myelin maintenance; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:2000147; P:positive regulation of cell motility; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0032000; P:positive regulation of fatty acid beta-oxidation; IMP:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; IMP:BHF-UCL.
DR   GO; GO:0010907; P:positive regulation of glucose metabolic process; IMP:BHF-UCL.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0010918; P:positive regulation of mitochondrial membrane potential; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; ISS:UniProtKB.
DR   GO; GO:0031340; P:positive regulation of vesicle fusion; ISS:UniProtKB.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IEA:Ensembl.
DR   GO; GO:0036211; P:protein modification process; TAS:ProtInc.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:UniProtKB.
DR   GO; GO:0030334; P:regulation of cell migration; TAS:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW.
DR   GO; GO:0097473; P:retinal rod cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:UniProtKB.
DR   CDD; cd01241; PH_PKB; 1.
DR   CDD; cd05595; STKc_PKB_beta; 1.
DR   DisProt; DP00304; -.
DR   Gene3D; 2.30.29.30; -; 1.
DR   IDEAL; IID00037; -.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR034677; Akt2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR039026; PH_PKB.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; ATP-binding;
KW   Carbohydrate metabolism; Cell membrane; Cytoplasm; Developmental protein;
KW   Diabetes mellitus; Disease variant; Disulfide bond; Endosome;
KW   Glucose metabolism; Glycogen biosynthesis; Glycogen metabolism;
KW   Glycoprotein; Kinase; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; Serine/threonine-protein kinase; Sugar transport;
KW   Transferase; Translation regulation; Transport; Ubl conjugation.
FT   CHAIN           1..481
FT                   /note="RAC-beta serine/threonine-protein kinase"
FT                   /id="PRO_0000085608"
FT   DOMAIN          5..108
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          152..409
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          410..481
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ACT_SITE        275
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         158..166
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         181
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         280
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000269|PubMed:12434148"
FT   BINDING         293
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000269|PubMed:12434148"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0007744|PubMed:22223895"
FT   MOD_RES         34
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         126
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         309
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000269|PubMed:12434148,
FT                   ECO:0000269|PubMed:15890450, ECO:0000269|PubMed:20059950,
FT                   ECO:0000269|PubMed:9512493"
FT   MOD_RES         447
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         451
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         474
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15890450,
FT                   ECO:0000269|PubMed:20059950, ECO:0007744|PubMed:19690332"
FT   MOD_RES         478
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   CARBOHYD        128
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        131
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        306
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        313
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000250"
FT   DISULFID        60..77
FT                   /evidence="ECO:0000250"
FT   DISULFID        297..311
FT                   /evidence="ECO:0000269|PubMed:12517337"
FT   VAR_SEQ         278..320
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_056930"
FT   VARIANT         17
FT                   /note="E -> K (in HIHGHH; exhibits plasma membrane
FT                   localization in serum-starved cells and produced
FT                   inappropriate tonic nuclear exclusion of FOXO1 in
FT                   preadipocytes; dbSNP:rs387906659)"
FT                   /evidence="ECO:0000269|PubMed:21979934"
FT                   /id="VAR_067309"
FT   VARIANT         188
FT                   /note="I -> V (in dbSNP:rs55859611)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040356"
FT   VARIANT         208
FT                   /note="R -> K (in dbSNP:rs35817154)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040357"
FT   VARIANT         274
FT                   /note="R -> H (in NIDDM; associated with typical metabolic
FT                   dyslipidemia with elevated fastin triglyceride, high VLDL
FT                   triglyceride/cholesterol ratios, low HDL cholesterol levels
FT                   and high small dense LDL levels; de novo lipogenesis and
FT                   liver fat are also significantly elevated in this subject;
FT                   dbSNP:rs121434593)"
FT                   /evidence="ECO:0000269|PubMed:15166380"
FT                   /id="VAR_067310"
FT   MUTAGEN         309
FT                   /note="T->A: Impairs interaction with TTC3; when associated
FT                   with A-474."
FT                   /evidence="ECO:0000269|PubMed:15890450,
FT                   ECO:0000269|PubMed:20059950"
FT   MUTAGEN         309
FT                   /note="T->E: Constitutively active; when associated with
FT                   D-474."
FT                   /evidence="ECO:0000269|PubMed:15890450,
FT                   ECO:0000269|PubMed:20059950"
FT   MUTAGEN         474
FT                   /note="S->A: Impairs interaction with TTC3; when associated
FT                   with A-309."
FT                   /evidence="ECO:0000269|PubMed:15890450,
FT                   ECO:0000269|PubMed:20059950"
FT   MUTAGEN         474
FT                   /note="S->D: Constitutively active; when associated with
FT                   E-309."
FT                   /evidence="ECO:0000269|PubMed:15890450,
FT                   ECO:0000269|PubMed:20059950"
FT   CONFLICT        478..481
FT                   /note="SIRE -> FREEKDLLMSLFVSLILFSDFSSLKSHSFSSNFILLSFSSLKK
FT                   (in Ref. 1; AAA36585)"
FT                   /evidence="ECO:0000305"
FT   STRAND          6..15
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   STRAND          17..20
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   STRAND          22..30
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   TURN            31..33
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   STRAND          34..40
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   STRAND          45..47
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   STRAND          52..56
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   STRAND          58..60
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   STRAND          62..65
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   STRAND          67..75
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   STRAND          86..92
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   HELIX           93..110
FT                   /evidence="ECO:0007829|PDB:1P6S"
FT   HELIX           149..151
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          152..160
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          162..171
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   TURN            172..174
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          177..184
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   HELIX           185..190
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   HELIX           194..205
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          215..220
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          222..230
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   HELIX           237..244
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   HELIX           249..268
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          280..283
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          289..291
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          298..300
FT                   /evidence="ECO:0007829|PDB:2UW9"
FT   STRAND          310..312
FT                   /evidence="ECO:0007829|PDB:2JDO"
FT   HELIX           314..316
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   HELIX           319..322
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          323..325
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   HELIX           331..345
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          351..353
FT                   /evidence="ECO:0007829|PDB:1GZK"
FT   HELIX           355..364
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          371..373
FT                   /evidence="ECO:0007829|PDB:1GZN"
FT   HELIX           375..384
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   TURN            389..391
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   TURN            393..395
FT                   /evidence="ECO:0007829|PDB:2X39"
FT   TURN            397..399
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   HELIX           400..404
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   HELIX           407..409
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   HELIX           414..418
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          431..434
FT                   /evidence="ECO:0007829|PDB:2JDR"
FT   STRAND          437..439
FT                   /evidence="ECO:0007829|PDB:1GZO"
FT   HELIX           441..444
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   TURN            470..472
FT                   /evidence="ECO:0007829|PDB:1O6L"
FT   STRAND          474..476
FT                   /evidence="ECO:0007829|PDB:3D0E"
FT   TURN            477..479
FT                   /evidence="ECO:0007829|PDB:3D0E"
SQ   SEQUENCE   481 AA;  55769 MW;  B18C87A7246BFB24 CRC64;
     MNEVSVIKEG WLHKRGEYIK TWRPRYFLLK SDGSFIGYKE RPEAPDQTLP PLNNFSVAEC
     QLMKTERPRP NTFVIRCLQW TTVIERTFHV DSPDEREEWM RAIQMVANSL KQRAPGEDPM
     DYKCGSPSDS STTEEMEVAV SKARAKVTMN DFDYLKLLGK GTFGKVILVR EKATGRYYAM
     KILRKEVIIA KDEVAHTVTE SRVLQNTRHP FLTALKYAFQ THDRLCFVME YANGGELFFH
     LSRERVFTEE RARFYGAEIV SALEYLHSRD VVYRDIKLEN LMLDKDGHIK ITDFGLCKEG
     ISDGATMKTF CGTPEYLAPE VLEDNDYGRA VDWWGLGVVM YEMMCGRLPF YNQDHERLFE
     LILMEEIRFP RTLSPEAKSL LAGLLKKDPK QRLGGGPSDA KEVMEHRFFL SINWQDVVQK
     KLLPPFKPQV TSEVDTRYFD DEFTAQSITI TPPDRYDSLG LLELDQRTHF PQFSYSASIR
     E
//
